

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
 - For example, a search on Aminosalicic Acid Tablets will result in anything that contains “Aminosalicic” OR “Acid” OR “Tablets”
 - A search for “Aminosalicic Acid Tablets” will result in anything that specifically contains “Aminosalicic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
 - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Publication Sort ascending	Target Online Fix Publication	Description
CARBINOXAMINE MALEATE	IMPURITIES/ <i>Organic Impurities</i>	<i>Second Supplement to USP41–NF36</i>	8786	22-Feb-2019	1-Mar-2019	NA	NA	<p>In <i>Standard stock solution</i>: Change (equivalent to 0.05 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.05 mg/mL of carbinoxamine) and 0.05 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the <i>Standard solution</i>: Change (equivalent to 0.001 mg/mL of USP Carbinoxamine Maleate RS free base) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS free base to: (equivalent to 0.001 mg/mL of carbinoxamine) and 0.001 mg/mL each of USP Carbinoxamine Related Compound A RS, USP Carbinoxamine Related Compound B RS, and USP Carbinoxamine Related Compound C RS (as the free base) AND In the <i>Analysis</i>: Change C_S = concentration of USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP Carbinoxamine Maleate RS (as the free base) Change The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Sample solution</i>, as obtained in the <i>Assay</i>. to: The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Standard solution</i>, as obtained in the <i>Assay</i>.</p>
METAXALONE	IDENTIFICATION/B.	<i>USP41–NF36</i>	2611	29-Mar-2019	1-Apr-2019	NA	NA	<p>The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Sample solution</i>, as obtained in the <i>Assay</i>. to: The retention time of the major peak of the <i>Sample solution</i> corresponds to that of the <i>Standard solution</i>, as obtained in the <i>Assay</i>.</p>

<u>Monograph Title</u>	<u>Section</u>	<u>Source Publication</u>	<u>Page Number</u>	<u>Errata Post Date</u>	<u>Errata Official Date</u>	<u>Target Errata Print Sort ascending</u>	<u>Target Online Fix Publication</u>	<u>Description</u>
SODIUM BICARBONATE	IMPURITIES/ <i>Carbonate</i>	USP42–NF37	4019	28-Jun-2019	1-Jul-2019	NA	NA	In <i>Analysis</i> : Change and promptly add 10 g of sodium bicarbonate to: and promptly add 10 g of Sodium Bicarbonate
2,5-DIHYDROXYBENZOIC ACID	REAGENTS AND REFERENCE TABLES/ <i>Reagent Specifications</i>	USP42–NF37	6097	22-Nov-2019	1-Dec-2019	NA	NA	Change [303-07-1]. to: [490-79-9]. In <i>Mobile phase</i> and <i>Chromatographic system</i> : Change Proceed as directed in the <i>Assay</i> under <i>Triazolam</i> . to: Proceed as directed in the <i>Assay</i> .
TRIAZOLAM TABLETS	<i>Uniformity of dosage units <905></i>	USP41–NF36	4202	28-Dec-2018	1-Jan-2019	NA	NA	AND In <i>Procedure</i> : Change Proceed as directed for <i>Procedure</i> in the <i>Assay</i> under <i>Triazolam</i> . to: Proceed as directed in the <i>Assay</i> .
CLOMIPHENE CITRATE	ADDITIONAL REQUIREMENTS/ <i>USP Reference Standards <11></i>	USP42–NF37	1068	31-May-2019	1-Jun-2019	NA	NA	In USP Clomiphene Related Compound A RS: Change (<i>E,Z</i>)-2-[4-(1,2-Diphenylethyl)phenoxy]- <i>N,N</i> -diethylethanamine hydrochloride. to: (<i>E,Z</i>)-2-[4-(1,2-Diphenylvinyl)phenoxy]- <i>N,N</i> -diethylethanamine hydrochloride. Also known as (<i>E,Z</i>)-2-[4-(1,2-Diphenylethenyl)phenoxy]- <i>N,N</i> -diethylethanamine hydrochloride.
FEXOFENADINE HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/ <i>USP Reference Standards <11></i>	<i>Revision Bulletin (Official November 01, 2018)</i>	Online	30-Aug-2019	1-Sep-2019	NA	NA	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/ <i>USP Reference Standards <11></i>	USP42–NF37	2518	26-Apr-2019	1-May-2019	NA	NA	In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl}-2-hydroxy-benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 ?[NOTE—This may be available as the sulfate salt (2:1).]? (USP 1-May-2019) to: 5-[2-(<i>tert</i> -Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
ALUMINA, MAGNESIA, AND SIMETHICONE ORAL SUSPENSION	SPECIFIC TESTS/ <i>Microbial Enumeration Tests <61> and Tests for Specified Microorganisms <62></i>	USP42–NF37	170	26-Jul-2019	1-Aug-2019	NA	NA	Change cfu/g to: cfu/mL

<u>Monograph Title</u>	<u>Section</u>	<u>Source Publication</u>	<u>Page Number</u>	<u>Errata Post Date</u>	<u>Errata Official Date</u>	<u>Target Errata Print Publication Sort ascending</u>	<u>Target Online Fix Publication</u>	<u>Description</u>
<121> INSULIN ASSAYS	ASSAY/Rabbit Blood Sugar Method—Quantitative	Revision Bulletin (Official May 01, 2019)	Online	27-Dec-2019	1-Jan-2020	NA	NA	In <i>Standard stock solution</i> : Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In <i>Sample stock solution</i> : Change of USP Insulin RS of the appropriate species. to: of the USP Insulin Reference Standard of the appropriate species. In <i>Labeling</i> : Change The label states the Latin binomial(s) of one or several <i>Salix</i> species included in the article. to: The label states the Latin binomial(s) of one or several <i>Salix</i> species included in the article. Dosage forms prepared with this article should bear the following statement: Not for use in children, women who are pregnant or nursing, or by persons with known sensitivity to aspirin. AND In <i>USP Reference Standards <11></i> : Delete (This monograph is postponed indefinitely.) In <i>Total unknown impurities</i> : Change NMT 1.0 to: NMT 1.0%
SALIX SPECIES BARK POWDER	ADDITIONAL REQUIREMENTS	USP42–NF37	5189	25-Jan-2019	1-Feb-2019	NA	NA	In <i>USP Reference Standards <11></i> : Delete (This monograph is postponed indefinitely.) In <i>Total unknown impurities</i> : Change NMT 1.0 to: NMT 1.0%
EPRINOMECTIN	IMPURITIES/Organic Impurities/Acceptance criteria	USP42–NF37	1627	31-May-2019	1-Jun-2019	NA	NA	In <i>USP Bendamustine Related Compound B RS</i> : Change 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid. $C_{16}H_{21}N_3O_3$ 303.36 to: 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid hydrochloride. $C_{16}H_{21}N_3O_3 \cdot xHCl$ In <i>Peptone diluent</i> : Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. <i>Trace mineral solution</i> : Prepare a solution containing In <i>Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis</i> : Change Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ AND Change Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION	ADDITIONAL REQUIREMENTS/ <i>USP Reference Standards <11></i>	USP42–NF37	487	27-Sep-2019	1-Oct-2019	NA	NA	In <i>USP Bendamustine Related Compound B RS</i> : Change 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid. $C_{16}H_{21}N_3O_3$ 303.36 to: 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid hydrochloride. $C_{16}H_{21}N_3O_3 \cdot xHCl$ In <i>Peptone diluent</i> : Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. <i>Trace mineral solution</i> : Prepare a solution containing In <i>Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis</i> : Change Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ AND Change Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
BACILLUS COAGULANS CAPSULES	ASSAY/Enumeration	USP42–NF37	4749	31-May-2019	1-Jun-2019	NA	NA	In <i>USP Bendamustine Related Compound B RS</i> : Change 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid. $C_{16}H_{21}N_3O_3$ 303.36 to: 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid hydrochloride. $C_{16}H_{21}N_3O_3 \cdot xHCl$ In <i>Peptone diluent</i> : Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. <i>Trace mineral solution</i> : Prepare a solution containing In <i>Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis</i> : Change Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ AND Change Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
HYPROMELLOSE ACETATE SUCCINATE	ASSAY	USP42–NF37	5772	25-Oct-2019	1-Nov-2019	NA	NA	In <i>USP Bendamustine Related Compound B RS</i> : Change 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid. $C_{16}H_{21}N_3O_3$ 303.36 to: 4-(1-Methyl-5-morpholino-1 <i>H</i> -benzimidazol-2-yl)butanoic acid hydrochloride. $C_{16}H_{21}N_3O_3 \cdot xHCl$ In <i>Peptone diluent</i> : Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. <i>Trace mineral solution</i> : Prepare a solution containing In <i>Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis</i> : Change Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ AND Change Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$

<u>Monograph Title</u>	<u>Section</u>	<u>Source Publication</u>	<u>Page Number</u>	<u>Errata Post Date</u>	<u>Errata Official Date</u>	<u>Target Errata Print Publication Sort ascending</u>	<u>Target Online Fix Publication</u>	<u>Description</u>
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	USP42–NF37	6079	26-Apr-2019	1-May-2019	NA	NA	In <i>Beef Extract/Microbial Content</i> : Change MT to: NMT
LOVASTATIN TABLETS	PERFORMANCE TESTS/ <i>Dissolution <711></i>	<i>First Supplement to USP42–NF37</i>	8727	26-Jul-2019	1-Aug-2019	NA	NA	In <i>Mobile phase</i> : Change Processed as directed in the <i>Assay</i> to: Proceed as directed in the <i>Assay</i> . In the <i>Standard stock solution</i> : Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the <i>Standard solution</i> : Change USP Carbinoxamine Maleate RS free base) to: carbinoxamine) AND In the <i>Analysis</i> : Change C_S = concentration of USP Carbinoxamine Maleate RS free base to: C_S = concentration of USP Carbinoxamine Maleate RS (as the free base)
CARBINOXAMINE MALEATE TABLETS	IMPURITIES/ <i>Organic Impurities</i>	<i>Second Supplement to USP41–NF36</i>	8788	22-Feb-2019	1-Mar-2019	NA	NA	In <i>Table 1</i> : Add Prednisolone sodium phosphate 1.00 — —
PREDNISOLONE SODIUM PHOSPHATE	<i>Related compounds</i>	USP41–NF36	3416	29-Mar-2019	1-Apr-2019	NA	NA	In <i>System suitability solution</i> : Change 0.25 µg/mL of USP Voriconazole RS to: 0.25 µg/mL of USP Voriconazole RS in <i>Mobile phase</i>
VORICONAZOLE	IMPURITIES/ <i>Voriconazole Related Compounds C and D</i>	USP42–NF37	4601	28-Jun-2019	1-Jul-2019	NA	NA	Change <i>Standardization</i> : Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced.
0.1 N POTASSIUM HYDROXIDE VS	REAGENTS AND REFERENCE TABLES/ <i>Solutions</i>	USP42–NF37	6185	22-Nov-2019	1-Dec-2019	NA	NA	to: <i>Standardization</i> : Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N hydrochloric acid VS. Titrate with the potassium hydroxide solution until a permanent pale-pink color is produced.

<u>Monograph Title</u>	<u>Section</u>	<u>Source Publication</u>	<u>Page Number</u>	<u>Errata Post Date</u>	<u>Errata Official Date</u>	<u>Target Errata Print Publication Sort ascending</u>	<u>Target Online Fix Publication</u>	<u>Description</u>
VITAMIN A	ADDITIONAL REQUIREMENTS	USP41–NF36	4327	28-Dec-2018	1-Jan-2019	NA	NA	Change Delete the following ?•USP Reference Standards <11> USP Retinyl Acetate RS USP Retinyl Palmitate RS ?(CN 1-May-2018) to: •USP Reference Standards <11> USP Retinyl Acetate RS USP Retinyl Palmitate RS
DACTINOMYCIN	IDENTIFICATION/ A. Ultraviolet Absorption <197U>/Acceptance criteria	USP42–NF37	1203	31-May-2019	1-Jun-2019	NA	NA	In Absorptivity: Change The absorptivity of the <i>Sample solution</i> at 445 nm is NLT 95.0% and NMT 103.0% that of the <i>Standard solution</i> . to: The absorptivity, calculated on the dried basis, of the <i>Sample solution</i> at 445 nm is NLT 95.0% and NMT 103.0% that of the <i>Standard solution</i> .
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED- RELEASE TABLETS	ADDITIONAL REQUIREMENTS/ USP Reference Standards <11>	Revision Bulletin (Official August 01, 2018)	Online	30-Aug-2019	1-Sep-2019	NA	NA	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]- ?,?-dimethyl.
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/Limit of S- Albuterol	USP42–NF37	Online	26-Apr-2019	1-May-2019	NA	NA	In Mobile phase: Change ?Acetonitrile, methanol, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.?(USP 1-May-2019) to: Acetonitrile and methanol (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.
BUSPIRONE HYDROCHLORIDE	IDENTIFICATION/B.	USP42–NF37	618	26-Jul-2019	1-Aug-2019	NA	NA	Change relative retention time to: retention time
POLYETHYLENE GLYCOL	CHEMICAL INFORMATION	USP42–NF37	5882	31-Jan-2020	1-Feb-2020	NA	NA	See https://www.uspnf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction
ARGATROBAN	CHEMICAL INFORMATION	USP41–NF36	346	22-Feb-2019	1-Mar-2019	NA	NA	See https://www.uspnf.com/sites/default/files/usp_pdf/EN/february_2019_errata_image1.pdf for correction
GUANABENZ ACETATE	IMPURITIES/ Limit of 2,6- Dichlorobenzaldehyde/ Chromatographic system	USP42–NF37	2129	31-May-2019	1-Jun-2019	NA	NA	In Column: Change 1.8-mm × 3-mm; to: 1.8-m × 3-mm;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Sort ascending	Target Online Fix Publication	Description
DESFLURANE	CHEMICAL INFORMATION	USP42–NF37	1230	27-Sep-2019	1-Oct-2019	NA	NA	Change (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether to: (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane.
FLUDROCORTISONE ACETATE TABLETS	IMPURITIES/ <i>Organic Impurities/</i> Table 1	<i>Second Supplement to</i> USP41–NF36	8843	22-Feb-2019	1-Mar-2019	NA	NA	In footnote a: Change 9-Fluoro-11 [?] ,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate. to: 9-Fluoro-11 [?] ,17,21-trihydroxypregn-4-ene-3,20-dione.
LIQUID GLUCOSE	ASSAY/ <i>Reducing Sugars</i>	USP42–NF37	5741	31-May-2019	1-Jun-2019	NA	NA	In the variable definition list in <i>Analysis</i> : Change C_U = concentration of dextrose equivalent to: C_U = concentration of Liquid Glucose
<55> BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS	D-VALUE DETERMINATION	USP42–NF37	6385	25-Oct-2019	1-Nov-2019	NA	NA	In the third paragraph in <i>Procedure</i> : Change stated spore filter to: stated spore titer
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	USP42–NF37	6104	26-Apr-2019	1-May-2019	NA	NA	In <i>Ferric Nitrate</i> : Change [10421-48-4]. to: [7782-61-8].
OXALIPLATIN INJECTION	IMPURITIES/ <i>Limit of Oxalic Acid/</i> <i>Chromatographic system</i>	<i>First Supplement to</i> USP42–NF37	8781	26-Jul-2019	1-Aug-2019	NA	NA	In <i>Column</i> : Change L31 to: L81
RUTIN	CHEMICAL INFORMATION	USP41–NF36	4841	29-Mar-2019	1-Apr-2019	NA	NA	Change 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4 <i>H</i> -chromen-4-one-3-yl 6- <i>O</i> -?-L-rhamnopyranosyl-?-D-glucoside [250249-75-3]. to: 3-Rhamnoglucoside of 5,7,3',4'-tetrahydroxyflavonol trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4 <i>H</i> -chromen-4-one-3-yl 6- <i>O</i> -?-L-rhamnopyranosyl-?-D-glucoside trihydrate [250249-75-3].
ZONISAMIDE	IMPURITIES/ <i>Organic Impurities</i>	USP42–NF37	4675	28-Jun-2019	1-Jul-2019	NA	NA	In <i>Analysis</i> : Change C_U = concentration of zonisamide related compound A in the <i>Sample solution</i> (mg/mL) to: C_U = concentration of zonisamide in the <i>Sample solution</i> (mg/mL)
25% TETRABUTYLAMMONIUM HYDROXIDE TS	REAGENTS AND REFERENCE TABLES/ <i>Solutions</i>	<i>Second Supplement to</i> USP42–NF37	9336	22-Nov-2019	1-Dec-2019	NA	NA	Change Transfer about 34.82 g to: Transfer about 77.1 g

<u>Monograph Title</u>	<u>Section</u>	<u>Source Publication</u>	<u>Page Number</u>	<u>Errata Post Date</u>	<u>Errata Official Date</u>	<u>Target Errata Print Publication Sort ascending</u>	<u>Target Online Fix Publication</u>	<u>Description</u>
BENZETHONIUM CHLORIDE	IMPURITIES/ <i>Organic Impurities/Acceptance criteria</i>	<i>First Supplement to USP41–NF36</i>	8297	25-Jan-2019	1-Feb-2019	NA	NA	In <i>Total impurities</i> : Change 1.0% to: NMT 1.0%
DIDANOSINE	IMPURITIES/ <i>Related Compounds</i>	<i>USP42–NF37</i>	1336	31-May-2019	1-Jun-2019	NA	NA	In <i>System suitability solution</i> : Change 0.5 mg/mL of didanosine from USP Didanosine System Suitability Mixture RS in <i>Diluent</i> to: 0.5 mg/mL of USP Didanosine System Suitability Mixture RS in <i>Diluent</i> Change 336.15 to: 336.14 AND Change [6385-02-0]; to: [67254-91-5]; AND Change UNII: 9MMQ0YER4E. to: UNII: 94NJ818U2W.
MECLOFENAMATE SODIUM	CHEMICAL INFORMATION	<i>USP42–NF37</i>	2706	30-Aug-2019	1-Sep-2019	NA	NA	In Row 3 of <i>Table 3</i> : Change Levalbuterol?—? —?— to: Levalbuterol?1.0?—?— Change relative retention time to: retention time
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/ <i>Organic Impurities</i>	<i>USP42–NF37</i>	2520	26-Apr-2019	1-May-2019	NA	NA	Change 972.84 to: 972.85
BUSPIRONE HYDROCHLORIDE TABLETS	IDENTIFICATION/ <i>B.</i>	<i>USP42–NF37</i>	621	26-Jul-2019	1-Aug-2019	NA	NA	This erratum applies to the <i>USP-NF ONLINE</i> platform only. See https://www.uspnf.com/sites/default/files/usp_pdf/EN/february_2019_errata_image1.pdf for correction
ALFADEX	CHEMICAL INFORMATION	<i>USP42–NF37</i>	5561	31-Jan-2020	1-Feb-2020	NA	NA	In the second equation in <i>Analysis</i> : Change $Result = (R_L ? P_B)/(P_A ? P_B)$ to: $Result = (R_L ? P_B)/(P_A ? P_B) \times 100$
DEXMEDETOMIDINE HYDROCHLORIDE	CHEMICAL INFORMATION	<i>USP41–NF36</i>	Online	22-Feb-2019	1-Mar-2019	NA	NA	
LEVOCARNITINE	IMPURITIES/ <i>Enantiomeric Purity</i>	<i>USP42–NF37</i>	2541	31-May-2019	1-Jun-2019	NA	NA	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Sort ascending	Target Online Fix Publication	Description
DESFLURANE	ADDITIONAL REQUIREMENTS/ <i>USP Reference Standards</i> <11>	<i>USP42–NF37</i>	1230	27-Sep-2019	1-Oct-2019	NA	NA	In USP Desflurane Related Compound A RS: Change Bis-(1,2,2,2-tetrafluoroethyl)ether. to: Bis-(1,2,2,2-tetrafluoroethyl)ether; Also known as: 1,1,1,2-Tetrafluoro-2-(1,2,2,2-tetrafluoroethoxy)ethane. In USP Mesna Related Compound A RS: Change 2-(Acetylthio)ethane-1-sulfonic acid. $C_4H_8O_4S_2$ 184.22 to: 2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride. $C_4H_7KO_4S_2$? KCl 296.86 AND In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98 In <i>Standardization</i> : Change previously dried at 100° to: previously dried at 110°
MESNA	ADDITIONAL REQUIREMENTS/ <i>USP Reference Standards</i> <11>	<i>Second Supplement to USP41–NF36</i>	8904	22-Feb-2019	1-Mar-2019	NA	NA	In USP Mesna Related Compound B RS: Change 2,2?-Disulfanediylbis(ethane-1-sulfonic acid). $C_4H_{10}O_6S_4$ 282.36 to: 2,2?-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride. $C_4H_8K_2O_6S_4$? NaCl 416.98 In <i>Standardization</i> : Change previously dried at 100° to: previously dried at 110°
REAGENTS AND REFERENCE TABLES	SOLUTIONS/ <i>0.01 M Edetate Disodium VS</i>	<i>USP42–NF37</i>	6179	31-May-2019	1-Jun-2019	NA	NA	In <i>Standardization</i> : Change previously dried at 100° to: previously dried at 110°
<1222> TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE	INTRODUCTION	<i>USP42–NF37</i>	8021	25-Oct-2019	1-Nov-2019	NA	NA	In paragraphs 4 and 5: Change a probability of a PNSU to: a PNSU

Pagination

- [First page](#) << [First](#)
- [Previous page](#) < [Previous](#)
- ...
- [Page 19](#)
- [Page 20](#)
- [Page 21](#)
- [Page 22](#)
- [Page 23](#)
- [Current page 24](#)
- [Page 25](#)
- [Page 26](#)
- [Page 27](#)

- [Next page](#) [Next](#) >
- [Last page](#) [Last](#) »